Andrew is an investor and entrepreneur with two decades of experience building, restructuring and acquiring companies in life sciences. A founding member of InCube's venture fund, he invests alongside his partners in medical devices and biotechnology, with board roles that have ranged from Channel Medsystems and WhiteSwell Medical to Rani Therapeutics and Metagenomi.
Andrew built a global sales force from scratch, grew revenues of synthetic DNA products to a market leadership position, and helped to negotiate a sale of Operon Technologies to QIAGEN.
Prior to joining InCube, Andrew served as a Partner in the Halo Funds, where he completed a Kauffman Fellowship and led investments in a portfolio of life science firms. Earlier in his career, Andrew served as Executive Vice President of sales, marketing and research for Operon Technologies. During his tenure there, Andrew built a global sales force from scratch and helped to negotiate a sale of the business to QIAGEN. Prior to Operon, Andrew held several roles in research operations at Genentech, Inc., where he managed protein therapeutic production and optimized cell lines for expression.
Andrew holds a Masters of Business Administration from Harvard University and a Bachelor's from the University of California at Berkeley.